Avenzo Therapeutics raised $150M in a Series A-1 financing led by New Enterprise Associates (NEA), Deep Track Capital, Sofinnova Investments, and Sands Capital to advance emerging oncology pipeline.

Avenzo Therapeutics, Inc. announced an oversubscribed $150 million Series A-1 financing, bringing the total capital raised since the company’s founding to $347 million. The financing round includes nine new investors and was led by New Enterprise Associates (NEA), Deep Track Capital, Sofinnova Investments, and Sands Capital. The proceeds from the financing will be used to advance Avenzo’s emerging oncology pipeline, particularly the potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor AVZO-021.